FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2405689775> ?p ?o ?g. }

• W2405689775 endingPage "04" @default.
• W2405689775 startingPage "P6" @default.
• W2405689775 abstract "Abstract Background: Treatment options for brain metastases are limited to local therapies due to the inability of most anti-cancer agents to cross the blood brain barrier (BBB). ANG1005 is a novel taxane derivative, being developed for targeted treatment of brain metastases. It consists of 3 paclitaxel molecules covalently linked to Angiopep-2 designed to cross the BBB and to penetrate malignant cells, regardless of location, via the low density lipoprotein (LDL) receptor related protein-1 (LRP-1) transport system. Methods: Adult patients with measurable recurrent brain metastases from breast cancer with, or without, leptomeningeal disease are currently being enrolled in this multi-center, open-label study (planned n=56). ANG1005 is administered IV at 600 mg/m2 every three weeks (one cycle) until disease progression, unacceptable toxicity or consent withdrawal. HER2+ patients are allowed to continue HER2 targeted therapies. The primary endpoint is intracranial objective response rate, as assessed by MRI using CNS RECIST 1.1. Secondary endpoints include duration of intracranial response, median progression-free survival, 3/6/12-month progression-free survival rate, overall survival at 6 months, extracranial objective response rate, safety and tolerability. Extracranial response is also assessed by CT using RECIST 1.1. An imaging sub-study, evaluating the use of 18F-FLT-PET in comparison to MRI, is also ongoing in 10 patients with measurable brain metastases from breast cancer, receiving ANG1005 IV at 550 mg/m2. Results: Accrual is ongoing and to date, 48 patients have been treated with a range of 1-18 cycles of ANG1005. Median age is 47 years (range: 26-65). Safety profile is similar to that of paclitaxel with myelosuppression as the predominating toxicity. Based on data from patients evaluated to date for intracranial response, 6/30 (20%) patients had a partial response (PR) and 17/30 (57%) had a stable disease (SD), as best response. A sub-analysis, based on breast cancer sub-type is presented below: Intracranial Response by Breast Cancer SubsetOutcome by CNS RECISTHER2- (n=13)HER2+ (n=17)TNBC (n=6)LMD (n=11)PR, n (%)1 (8%)5 (29%)1 (17%)4 (36%)SD, n (%)6 (46%)10 (59%)2 (33%)5 (45%)PD, n (%)6 (46%)2 (12%)3 (50%)2 (18%)TNBC, triple-negative breast cancer, a sub-group of HER2-; LMD, leptomeningeal disease, including 3 HER2- and 8 HER2+ patients The longest duration on treatment is for 18 cycles, seen in a patient with an intracranial PR that sustained for 10 cycles; the treatment is still ongoing. Extracranial tumor evaluations were completed in 14 patients, all showing disease control including in those previously treated with paclitaxel. One (7%) patient had a PR and 13 (93%) patients had an SD. Conclusions: CNS activity was observed in all subsets of breast cancer, suggesting that ANG1005 is a promising therapy for treatment of brain and leptomeningeal metastases from breast cancer. ANG1005 treatment also resulted in disease control in extracranial lesions, including patients previously treated with paclitaxel. The dose and treatment regimen were well tolerated with a safety profile similar to paclitaxel. Updated efficacy and safety data will be presented at the meeting. Citation Format: Tang S-C, Bates S, Kesari S, Brenner AJ, Anders CK, Garcia A, Ibrahim NK, Tkaczuk KHR, Kumthekar P. A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant taxane derivative, in breast cancer patients with recurrent CNS metastases. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-17-04." @default.
• W2405689775 created "2016-06-24" @default.
• W2405689775 creator A5010750303 @default.
• W2405689775 creator A5013592290 @default.
• W2405689775 creator A5041912679 @default.
• W2405689775 creator A5063863193 @default.
• W2405689775 creator A5075020011 @default.
• W2405689775 creator A5084802794 @default.
• W2405689775 creator A5087525855 @default.
• W2405689775 creator A5090158071 @default.
• W2405689775 creator A5091750059 @default.
• W2405689775 date "2016-02-15" @default.
• W2405689775 modified "2023-09-25" @default.
• W2405689775 title "Abstract P6-17-04: A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant taxane derivative, in breast cancer patients with recurrent CNS metastases" @default.
• W2405689775 doi "https://doi.org/10.1158/1538-7445.sabcs15-p6-17-04" @default.
• W2405689775 hasPublicationYear "2016" @default.
• W2405689775 type Work @default.
• W2405689775 sameAs 2405689775 @default.
• W2405689775 citedByCount "1" @default.
• W2405689775 countsByYear W24056897752019 @default.
• W2405689775 crossrefType "journal-article" @default.
• W2405689775 hasAuthorship W2405689775A5010750303 @default.
• W2405689775 hasAuthorship W2405689775A5013592290 @default.
• W2405689775 hasAuthorship W2405689775A5041912679 @default.
• W2405689775 hasAuthorship W2405689775A5063863193 @default.
• W2405689775 hasAuthorship W2405689775A5075020011 @default.
• W2405689775 hasAuthorship W2405689775A5084802794 @default.
• W2405689775 hasAuthorship W2405689775A5087525855 @default.
• W2405689775 hasAuthorship W2405689775A5090158071 @default.
• W2405689775 hasAuthorship W2405689775A5091750059 @default.
• W2405689775 hasConcept C121608353 @default.
• W2405689775 hasConcept C126322002 @default.
• W2405689775 hasConcept C143998085 @default.
• W2405689775 hasConcept C197934379 @default.
• W2405689775 hasConcept C203092338 @default.
• W2405689775 hasConcept C2775930923 @default.
• W2405689775 hasConcept C2776694085 @default.
• W2405689775 hasConcept C2777511904 @default.
• W2405689775 hasConcept C2778164965 @default.
• W2405689775 hasConcept C2778375690 @default.
• W2405689775 hasConcept C2779013556 @default.
• W2405689775 hasConcept C2779786085 @default.
• W2405689775 hasConcept C2779984678 @default.
• W2405689775 hasConcept C2780739268 @default.
• W2405689775 hasConcept C31760486 @default.
• W2405689775 hasConcept C530470458 @default.
• W2405689775 hasConcept C535046627 @default.
• W2405689775 hasConcept C71924100 @default.
• W2405689775 hasConceptScore W2405689775C121608353 @default.
• W2405689775 hasConceptScore W2405689775C126322002 @default.
• W2405689775 hasConceptScore W2405689775C143998085 @default.
• W2405689775 hasConceptScore W2405689775C197934379 @default.
• W2405689775 hasConceptScore W2405689775C203092338 @default.
• W2405689775 hasConceptScore W2405689775C2775930923 @default.
• W2405689775 hasConceptScore W2405689775C2776694085 @default.
• W2405689775 hasConceptScore W2405689775C2777511904 @default.
• W2405689775 hasConceptScore W2405689775C2778164965 @default.
• W2405689775 hasConceptScore W2405689775C2778375690 @default.
• W2405689775 hasConceptScore W2405689775C2779013556 @default.
• W2405689775 hasConceptScore W2405689775C2779786085 @default.
• W2405689775 hasConceptScore W2405689775C2779984678 @default.
• W2405689775 hasConceptScore W2405689775C2780739268 @default.
• W2405689775 hasConceptScore W2405689775C31760486 @default.
• W2405689775 hasConceptScore W2405689775C530470458 @default.
• W2405689775 hasConceptScore W2405689775C535046627 @default.
• W2405689775 hasConceptScore W2405689775C71924100 @default.
• W2405689775 hasIssue "4_Supplement" @default.
• W2405689775 hasLocation W24056897751 @default.
• W2405689775 hasOpenAccess W2405689775 @default.
• W2405689775 hasPrimaryLocation W24056897751 @default.
• W2405689775 hasRelatedWork W1971716849 @default.
• W2405689775 hasRelatedWork W2005692436 @default.
• W2405689775 hasRelatedWork W2074061081 @default.
• W2405689775 hasRelatedWork W2163622510 @default.
• W2405689775 hasRelatedWork W2329858520 @default.
• W2405689775 hasRelatedWork W2406128178 @default.
• W2405689775 hasRelatedWork W2944154894 @default.
• W2405689775 hasRelatedWork W3083051559 @default.
• W2405689775 hasRelatedWork W4210581512 @default.
• W2405689775 hasRelatedWork W4281907835 @default.
• W2405689775 hasVolume "76" @default.
• W2405689775 isParatext "false" @default.
• W2405689775 isRetracted "false" @default.
• W2405689775 magId "2405689775" @default.
• W2405689775 workType "article" @default.